Physician profile

Ryan C Chua

Pulmonary Disease · Leominster, MA

NPI 1659534501

$10,525.82

in general payments reported to CMS, 2019-2025

42 companies · $2,831 in 2025

The $2,831 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$6,467.45
Education$174.32

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $2,734.61 2019-2025 Fasenra, Airsupra, Tezspire
Glaxosmithkline, LLC. $2,649.38 2019-2025 Trelegy Ellipta, Nucala, Arexvy
Boehringer Ingelheim Pharmaceuticals, INC. $705.82 2019-2025 Ofev, Spiriva Respimat, Stiolto Respimat
Regeneron Healthcare Solutions, INC. $569.14 2019-2025 Dupixent
Genzyme Corporation $551.87 2019-2025
Actelion Pharmaceuticals US, INC. $369.37 2019-2025 Opsumit, Uptravi, Opsynvi
Electromed, INC. $250.62 2022-2025 Smartvest
Takeda Pharmaceuticals U.S.A., INC. $188.80 2022-2025 Glassia, Takhzyro
United Therapeutics Corporation $185.99 2023-2025 Tyvaso, Tyvaso
Amgen INC. $176.93 2023-2025 Tezspire
Mallinckrodt Hospital Products INC. $174.72 2023 Acthar
Novartis Pharmaceuticals Corporation $160.32 2019-2024
Sanofi-Aventis U.S. LLC $160.18 2020-2025
Axsome Therapeutics, INC. $137.59 2023-2025 Sunosi
Baxter Healthcare $117.08 2024-2025 Hillrom - Vest System Model 105 Home Care
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Insmed, INC. $105.99 2020-2025 Arikayce, Brinsupri
Pfizer INC. $102.78 2019-2022
Inspire Medical Systems, INC. $99.17 2024-2025 Inspire
Sunovion Pharmaceuticals INC. $89.44 2019-2020
Mylan Specialty L.P. $87.58 2019-2023 Yupelri
Harmony Biosciences LLC $87.38 2020-2022
Jazz Pharmaceuticals INC. $84.95 2021-2022
Abbvie INC. $71.99 2022-2025
Inogen, INC. $71.01 2024-2025
E.R. Squibb & Sons, L.L.C. $65.86 2022-2024 Camzyos, Eliquis
Teva Pharmaceuticals USA, INC. $56.38 2020-2021
Verona Pharma, INC. $50.38 2025 Ohtuvayre
Itamar Medical INC $49.79 2022
Advanced Respiratory, INC $48.90 2021
Genentech USA, INC. $41.40 2019
Philips North America LLC $40.56 2019-2022
Ethicon INC. $37.88 2021
Merck Sharp & Dohme LLC $34.61 2019-2020
Bayer Healthcare Pharmaceuticals INC. $22.76 2019
Allergan, INC. $21.42 2020
Lilly USA, LLC $20.56 2025 Zepbound
Olympus America INC. $19.54 2019
Ars Pharmaceuticals Operations, INC. $18.21 2025 Neffy
Grifols USA, LLC $17.21 2019
Shire North American Group INC $16.99 2019
Resmed Corp $15.99 2023
Viatris Specialty LLC $14.67 2025 Yupelri

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ryan C Chua

$10,525.82

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $2,831 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/496071/ryan-c-chua

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.